Slow Uptake In Minnesota For Promising New Covid-19 Therapy
Dosages of monoclonal antibodies, a promising new treatment therapy for COVID-19, started being distributed to states just over a month ago with hopes that this treatment can help reduce and prevent serious complications associated with the disease. Doctors and health professionals were initially worried that hospitals would not be able to keep up with the demand for the treatment, expecting it to be like opening the flood gates. Contrary to expectations, the distribution of the new therapy has been much less than expected for a variety of reasons including patient hesitancy, lack of staffing, and lack of hospital space to set up infusion centers. In this article, various doctors, including Andrew Olson, MD, Associate Professor in the Division of Pediatric Hospital Medicine at the University of Minnesota, discuss the uses and benefits of this relatively new and promising treatment along with the logistical concerns that come with running the infusion distribution throughout the nation. To learn more about medical experts’ views on this antibody treatment and to read the full article, follow this link.